clinical research, he frequently collaborates with basic scientists in his research activities.

He has published more than 500 original articles, review articles, abstracts and book chapters. Dr. Gish is also actively involved in numerous professional societies, and is a long-term member of the American Association for the Study of Liver Disease, European Association for the Study of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society of Transplant Physicians. He is a fellow of both the American College of Physicians and a long-term member of the American Association for the Study of Liver Disease. Dr. Gish has served on the editorial boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of Viral Hepatitis. He has co-authored a public health policy for liver health in Vietnam and is also assisting with the development of health care policies in Armenia and the Philippines. In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical Professor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for Hepatobiliary Disease and Abdominal Transplantation (C.H.A.T.). In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. Gish Consultants LLC to provide consultative support to Hepatology Centers and Liver Transplant Programs who wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Today, Dr. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas where he continues to teach and is a senior consultant at St Josephs Medical Center in Phoenix.

Robert G. Gish MD
Dr. Gish began his medical training in 1974 when he was enrolled into the Pharmacy School at the University of Kansas. He transferred to the University of Kansas Medical School in 1977 and finished his MD degree in 1980. Dr. Gish went on to complete a 3 year Internal Medicine residency at the University of California, San Diego and a 4 year Gastroenterology and Hepatology fellowship at the University of California Los Angeles during which time he was awarded the NIH Physician Scientist Award to study calcium signaling in liver cells. After completing his training, Dr. Gish moved to San Francisco and took a position at the California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital). He became the CoMedical Director of the Liver Transplant Program in 1988 and then the Medical Director of the Liver Transplant Program in 1994. In that role he developed an outreach program that eventually served over 35,000 patients in the Northern California and Nevada regions, and made the CPMC a leading liver transplant center.

Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, Liver Centers and Liver Transplant Programs bio artificial liver, and public policy especially related to liver cancer, liver transplantation and viral Dr. Gish became the Co-Medical Director of the hepatitis. Although his primary research focus is Liver Transplant Program at the California Pacific

Medical Center in 1988. He developed an outreach program that now serves over 35,000 patients in Northern California and Nevada, making CPMC a leading liver transplant center. Dr. Gish joined the faculty of University of California San Diego in several capacities, including Director of the Center for Hepatobiliary Disease and Abdominal Transplantation. He also became Director of Clinical Hepatology at UCSD in 2013. His research on Regional Review Boards may also change public policies on liver transplants in the United States. This research supports the replacement of the current RRB system with a national review board that uses clinical expertise to assign priorities. The goal of this system is to allocate organs equitably while improving compliance with the HHS Final Rule.

Health Policy and Patient Advocacy Dr. Gish has been involved with patient care and patient advocacy groups dating back to 1988 when he became involved with the American Liver Foundation. Since that time, he has been active with a number of organizations including the National Viral Hepatitis Roundtable, Viral Hepatitis Action Coalition, the Fair Foundation, Center for Eradication of Viral Hepatitis/Asia Pacific Organization, HEPDART, World Health Organization, Centers for Disease Control, Hepatitis B Free (San Francisco and San Diego), Hepatitis B Foundation, Hepatitis C Caring Ambassadors, Viral Hepatitis Foundation, and Hepatitis Foundation for Vietnam.

Dr. Gishs international advocacy career focuses on public policy in Vietnam, Philippines, and ArmeResearch nia. His team wrote a white paper on Health Care and Liver Health in Vietnam that was published in Dr. Gishs pharmaceutical research includes a a peer-reviewed publication. Additional projects 2011 Phase III study on the effects of BI 201335, in Vietnam and the Philippines include protocols pegylated interferon-a and ribavirin on patients in- that advance screening for viral hepatitis and linkfected with genotype 1 chronic hepatitis C. He is age to care, as well as global liver health issues also the principle investigator in an ongoing study including obesity, fatty liver, and alcohol induced on screening for viral hepatitis and its economic liver disease. The newest addition to Dr. Gishs effects on healthcare. Another study currently be- global health policy work is in Armenia, where ing conducted by Dr. Gish involves the analysis of he is developing a white paper for that countrys liver patients at UCSD. 5-year Liver Health Policy. Dr. Gish is the principle investigator in a study that was started in 2012 to investigate the effects of PSI-352938, PSE-7977 and Ribavirin in patients with Chronic HCV. He is also currently investigating the challenges of educating Asians in San Diego County on Hepatitis B in a study that began in 2012. Dr. Gish was an investigator in studies that led to the development of tests for HBV and HCV and most recently a 2005 study on DNA HBV genotyping and molecular profiling in newly recruited, HBV and HCV patients. He was also an investigator in a 2006 study that used molecular signatures to predict interferon response in patients infected with hepatitis C.

ROBERT G. GISH CONSULTANTS, LLC

Providing Medical Consulting Services to Pharma, CME Organizations, Academic and Private Institutions